H
Helmut G. Rennke
Researcher at Brigham and Women's Hospital
Publications - 267
Citations - 35414
Helmut G. Rennke is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Renal function & Kidney. The author has an hindex of 77, co-authored 256 publications receiving 33959 citations. Previous affiliations of Helmut G. Rennke include Boston Medical Center & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury
Jacob L. Simons,Abraham P. Provoost,Abraham P. Provoost,Sharon Anderson,Sharon Anderson,Helmut G. Rennke,Helmut G. Rennke,Julia L. Troy,Julia L. Troy,Barry M. Brenner,Barry M. Brenner +10 more
TL;DR: It is concluded that systemic and glomerular hypertension govern the development of UpV and FGS.
Journal Article
Mechanism of proximal tubule brush border loss and regeneration following mild renal ischemia
TL;DR: The results strongly suggest that in reversibly injured proximal tubule cells regeneration of the brush border occurs primarily by a process of recycling of damaged, previously incorporated membrane.
Journal ArticleDOI
Converting enzyme inhibitor therapy limits progressive glomerular injury in rats with renal insufficiency
TL;DR: It is suggested that antihypertensive therapy directed at reducing the glomerular capillary pressure could retard the progressive loss of renal function in patients whose functional renal mass has been reduced by disease.
Journal ArticleDOI
Effect of psychological stress on the induction of arthritis in rats.
Malcolm P. Rogers,David E. Trentham,W. Joseph McCune,Barry I. Ginsberg,Helmut G. Rennke,Peter Reich,John R. David +6 more
TL;DR: This study provides a unique demonstration that psychosomatic processes can influence an animal mode of autoimmunity and abrogated the development of arthritis in rats immunized with type II collagen.
Journal ArticleDOI
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Vivek Kumar,Atul B. Shinagare,Helmut G. Rennke,Sandeep Ghai,Jochen H. Lorch,Patrick A. Ott,Osama E. Rahma +6 more
TL;DR: The pooled data from these reports suggest that anti-programmed death-ligand 1 inhibitors have reasonable safety and efficacy among organ transplant patients, which warrants testing in clinical trials.